Daniel Mertens
Overview
Explore the profile of Daniel Mertens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
3120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bloehdorn J, Braun A, Taylor-Weiner A, Jebaraj B, Robrecht S, Krzykalla J, et al.
Nat Commun
. 2021 Sep;
12(1):5395.
PMID: 34518531
Knowledge of the genomic landscape of chronic lymphocytic leukemia (CLL) grows increasingly detailed, providing challenges in contextualizing the accumulated information. To define the underlying networks, we here perform a multi-platform...
12.
Pan H, Renaud L, Chaligne R, Bloehdorn J, Tausch E, Mertens D, et al.
Cancer Discov
. 2021 May;
11(9):2266-2281.
PMID: 33972312
Epigenetic alterations, such as promoter hypermethylation, may drive cancer through tumor suppressor gene inactivation. However, we have limited ability to differentiate driver DNA methylation (DNAme) changes from passenger events. We...
13.
Bloehdorn J, Krzykalla J, Holzmann K, Gerhardinger A, Jebaraj B, Bahlo J, et al.
Haematologica
. 2021 Mar;
107(3):615-624.
PMID: 33730841
Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) can induce long-term remissions in patients with chronic lymphocytic leukemia. Treatment efficacy with Bruton's tyrosine kinase inhibitors was found similar to FCR in...
14.
Zapatka M, Tausch E, Ozturk S, Yosifov D, Seiffert M, Zenz T, et al.
Haematologica
. 2021 Mar;
107(3):604-614.
PMID: 33691380
Clonal evolution is involved in the progression of chronic lymphocytic leukemia (CLL). In order to link evolutionary patterns to different disease courses, we performed a long-term longitudinal mutation profiling study...
15.
16.
Tausch E, Beck P, Schlenk R, Jebaraj B, Dolnik A, Yosifov D, et al.
Haematologica
. 2020 Oct;
105(10):2440-2447.
PMID: 33054084
Next generation sequencing studies in Chronic lymphocytic leukemia (CLL) have revealed novel genetic variants that have been associated with disease characteristics and outcome. The aim of this study was to...
17.
Yosifov D, Bloehdorn J, Dohner H, Lichter P, Stilgenbauer S, Mertens D
Sci Data
. 2020 May;
7(1):133.
PMID: 32358561
Acquired resistance to chemotherapy is an important clinical problem and can also occur without detectable cytogenetic aberrations or gene mutations. Chronic lymphocytic leukemia (CLL) is molecularly well characterized and has...
18.
Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J, et al.
Blood
. 2020 Mar;
135(26):2402-2412.
PMID: 32206772
Genetic parameters are established prognostic factors in chronic lymphocytic leukemia (CLL) treated with chemoimmunotherapy, but are less well studied with novel compounds. We assessed immunoglobulin heavy variable chain (IGHV) mutation...
19.
Wierzbinska J, Toth R, Ishaque N, Rippe K, Mallm J, Klett L, et al.
Genome Med
. 2020 Mar;
12(1):29.
PMID: 32188505
Background: In cancer, normal epigenetic patterns are disturbed and contribute to gene expression changes, disease onset, and progression. The cancer epigenome is composed of the epigenetic patterns present in the...
20.
Ferrante F, Giaimo B, Bartkuhn M, Zimmermann T, Close V, Mertens D, et al.
Nucleic Acids Res
. 2020 Feb;
48(7):3496-3512.
PMID: 32107550
Aberrant Notch signaling plays a pivotal role in T-cell acute lymphoblastic leukemia (T-ALL) and chronic lymphocytic leukemia (CLL). Amplitude and duration of the Notch response is controlled by ubiquitin-dependent proteasomal...